OSUR צמיחה צפויה ברווח נקי למניה השנה OraSure Technologies

OraSure Technologies (OSUR) is facing margin pressure due to declining demand for COVID tests and fierce competition. The annual EPS change ratio clearly demonstrates these fluctuations, where the 36.60 metric serves as the target level. High pipeline automation minimizes manual labor, while steady sales of sample collection systems support cash flow, offsetting the impact of the post-pandemic slump.

OraSure Technologies (OSUR) is currently transforming its business model, shifting from pandemic-era products toward scaling molecular diagnostic systems. The annual earnings per share trajectory reflects EPS dynamics relative to the previous year, allowing for an assessment of this pivot's effectiveness through the lens of net income; meanwhile, sharp fluctuations in the trend line require correlation with debt load to accurately calculate the cost of capital.